semaglutide liver damage improves metabolic disease partly via intrahepatic GLP-1 receptors • The hepatic GLP-1R is expressed within T cells and endothelial cells • Liver sinusoidal endothelial cell GLP-1 receptors transduce hepatic GLP-1 can semaglutide cause liver damage

5-amino-1MQ blocks that enzyme, slowing the breakdown

Williard WC, Collin C, Casper ES, Hajdu SI, Brennan MF

Others prefer Zepbound if appetite control improves adherence despite stronger early effects

Clinical Trials Retatrutide is still moving through clinical development, meaning trials are ongoing

However, there is a gap in knowledge as to understanding whether once weekly semaglutide would lead to reductions in symptoms and physical limitations and to improved exercise function, in addition to weight loss, in patients with heart failure with preserved ejection fraction and obesity

The FDA approved Liraglutide, the first generic of a once-daily GLP-1 injection, in December 2024